Can different thyroid tumor types be distinguished by polymerase chain reaction-based K-ras mutation detection?

被引:2
作者
Apple, SK
Alzona, MC
Alzona, MC
Jahromi, SA
Grody, WW
机构
[1] Univ Calif Los Angeles, Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90024 USA
[2] Univ Calif Los Angeles, Sch Med, Dept Pediat, Los Angeles, CA 90024 USA
来源
MOLECULAR DIAGNOSIS | 1998年 / 3卷 / 03期
关键词
follicular adenoma; follicular carcinoma; papillary carcinoma; oncogenes;
D O I
10.1016/S1084-8592(98)80032-5
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Background: Thyroid tumors have mutations of the ms oncogenes, although the prognostic and diagnostic significance of this remains unclear. Usually, thyroid follicular adenoma, follicular carcinoma, and papillary carcinoma are easy to differentiate histologically. Occasionally, follicular carcinoma may be difficult to separate from the follicular variant of papillary carcinoma, and a molecular test to help differentiate the two would be critical, as their behavior and clinical management differ. In earlier reports, K-ras mutations have been suggested as such a marker. Methods and Results: To study genetic differences between thyroid tumors, the authors examined 79 cases (58 papillary carcinomas, 12 follicular carcinomas, and 9 adenomas) for the presence of a K-ras mutation in codon 12 by polymerase chain reaction and restriction endonuclease digestion. Only six papillary carcinomas (12%) showed a K-ras mutation; no mutations were detectable in the other thyroid tumors. Conclusion: K-ras mutation analysis does not help differentiate thyroid tumor types.
引用
收藏
页码:143 / 148
页数:6
相关论文
共 24 条
[1]  
Apple SK, 1996, AM J CLIN PATHOL, V105, P321
[2]  
BOS JL, 1989, CANCER RES, V49, P4682
[3]   Ras oncogene mutations in thyroid tumors - Polymerase chain reaction-restriction-fragment-length polymorphism analysis from paraffin-embedded tissues [J].
Capella, G ;
MatiasGuiu, X ;
Ampudia, X ;
deLeiva, A ;
Perucho, M ;
Prat, J .
DIAGNOSTIC MOLECULAR PATHOLOGY, 1996, 5 (01) :45-52
[4]  
FURTH ME, 1987, ONCOGENE, V1, P47
[5]  
JOHNSON TL, 1987, AM J PATHOL, V127, P60
[6]   RAS ONCOGENE MUTATIONS IN BENIGN AND MALIGNANT THYROID NEOPLASMS [J].
KARGA, H ;
LEE, JK ;
VICKERY, AL ;
THOR, A ;
GAZ, RD ;
JAMESON, JL .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1991, 73 (04) :832-836
[7]  
LEMOINE NR, 1989, ONCOGENE, V4, P159
[8]  
LEMOINE NR, 1988, CANCER RES, V48, P4459
[9]   SELECTIVE ACTIVATION OF RAS ONCOGENES IN FOLLICULAR AND UNDIFFERENTIATED THYROID CARCINOMAS [J].
MANENTI, G ;
PILOTTI, S ;
RE, FC ;
DELLAPORTA, G ;
PIEROTTI, MA .
EUROPEAN JOURNAL OF CANCER, 1994, 30A (07) :987-993
[10]  
MASSIN JP, 1984, CANCER, V53, P982, DOI 10.1002/1097-0142(19840215)53:4<982::AID-CNCR2820530427>3.0.CO